Almac forms analytical group, increases capacity

Almac-forms-analytical-group-increases-capacity.png
(Image: Almac Group)

Almac’s Sciences Business Unit has combined its capabilities with BioClin to form an analytical group spanning the UK, Europe, and North America.

The contract development and manufacturing organization (CDMO) Almac Group acquired BioClin Research Laboratories in 2017.

BioClin provides analytical services, including cGMP pharmaceutical and biopharmaceutical analysis, GMP microbiology testing, and GLP bioanalysis.

The company’s 14,000 square foot facility – located in Athlone, Ireland, two hours from Almac’s headquarters in Craigavon – is GLP certified (INAB), cGMP certified (HPRA) and FDA registered.

As of October 1, BioClin has been renamed under the Almac Sciences brand, which employs 150 analysts across three locations.

Additionally, the company has increased capacity at its PA-based facility by 30% to meet client demand.

The 2,500 square foot laboratory provides good manufacturing practice (GMP) analytical services, including analytical method development and validation, GMP stability studies, as well as clinical and commercial product release.

Almac also has announced the successful inspection of Almac Pharma Services (Ireland) at its European campus in Dundalk, by the Health Products Regulatory Authority (HPRA).

Since January, the CDMO has invested £10m to establish analytical laboratories and commercial packaging suites to meet client needs within the European Union.